Systemic treatment of advanced colorectal cancer: FOLFOX or XELOX?

Sebastian Ochenduszko
Oncol Clin Pract 2008;4(1):8-14.

open access

Vol 4, No 1 (2008)
REVIEW ARTICLES
Published online: 2008-02-28

Abstract

Chemotherapy with oxaliplatin and fluoropirymidines is one of the standard regimens for treatment of advanced colorectal cancer in the first-line setting. Capecitabine is an oral fluoropirymidine showing equal efficacy in monotherapy of colorectal cancer as intravenous 5-fluorouracil. Recently, the results of few randomized phase III trials comparing the efficacy and tolerability of XELOX (capecitabine + oxaliplatin) vs. FOLFOX/FUOX/FUFOX (infusional 5-flurorouracil + oxaliplatin) regimens in the first-line treatment of advanced colorectal cancer have been published. The results of few studies indicate marginally inferior activity of XELOX, whereas preliminary data from other two studies prove that XELOX and FOLFOX have equal efficacy. After adding bevacizumab, the activity of the two regimens remains comparable, however it seems that bevacizumab increases the activity of XELOX regimen more compared to FOLFOX, and in one observational study progression free survival in XELOX + bevacizumab arm was slightly longer. Toxicity of these two regimens does not differ significantly. Based on available data, it seems that FOLFOX remains the standard treatment regimen for advanced colorectal cancer in the first-line setting.

Keywords

oxaliplatin; 5-fluorouracil; capecitabine; XELOX; FOLFOX; bevacizumab

About this article
Title

Systemic treatment of advanced colorectal cancer: FOLFOX or XELOX?

Journal

Oncology in Clinical Practice

Issue

Vol 4, No 1 (2008)

Pages

8-14

Published online

2008-02-28

Bibliographic record

Oncol Clin Pract 2008;4(1):8-14.

Keywords

oxaliplatin
5-fluorouracil
capecitabine
XELOX
FOLFOX
bevacizumab

Authors

Sebastian Ochenduszko

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl